Welcome to our dedicated page for Quoin Pharmaceuticals Ltd. SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Quoin Pharmaceuticals Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Quoin Pharmaceuticals Ltd.'s regulatory disclosures and financial reporting.
Quoin Pharmaceuticals Ltd. (QNRX) reports a Rule 506(b) Regulation D private offering of equity, warrants, and underlying securities, with total gross proceeds of $50,000,649 assuming cash exercise of all warrants issued in the private placement. The notice states that the total amount has been sold and no amount remains to be offered. Leerink Partners, BTIG, and Lake Street Capital Markets act as placement agents and are entitled to aggregate fees equal to 6.0% of gross offering proceeds based on full warrant exercise. Proceeds are for general working capital, and the company notes some portion may indirectly fund salaries, including those of executive officers.
Quoin Pharmaceuticals Ltd. (QNRX) reported that the U.S. FDA has granted Rare Pediatric Disease (RPD) Designation to its lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS). This is the second RPD designation for QRX003, following an earlier RPD designation for Netherton Syndrome.
The RPD program is intended to support development of therapies for serious diseases that primarily affect individuals under 18 years of age. If a New Drug Application for QRX003 is eventually approved, Quoin may qualify to receive a transferable Priority Review Voucher. Quoin also stated that, with an IND cleared by the FDA, it is preparing to initiate a Phase 2 clinical study of QRX003 in PSS before the end of 2026, with plans to enroll up to 12 pediatric and adult patients in the U.S. and Europe.
Quoin Pharmaceuticals, Ltd. (QNRX) director and Chief Operating Officer Denise P. Carter reported net purchases on August 31, 2026. She purchased 20,490 ADSs at $4.88 per ADS in a private placement and acquired 10,245 ordinary warrants with a $6.10 exercise price, giving the right to buy 10,245 ADSs. Each ADS represents 35 ordinary shares. The warrants are immediately exercisable, subject to a beneficial ownership cap, and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following the ADS purchase, Carter directly owns 37,709 ADSs.
Quoin Pharmaceuticals, Ltd. (QNRX) reports that Chief Executive Officer Michael Myers purchased both ADSs and warrants in a private placement. On 2026-08-31, he acquired 20,490 ADSs at a combined purchase price of $4.88 per ADS plus accompanying ordinary warrants, increasing his direct ADS holdings to 37,713. In the same transaction, he acquired 10,245 Ordinary Warrants, each exercisable for one ADS at an exercise price of $6.10 per ADS, subject to a beneficial ownership cap. The warrants are exercisable immediately and will expire on the earlier of five years from issuance or 30 days after a public announcement that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome.
Quoin Pharmaceuticals, Ltd. (QNRX) reported that Chief Financial Officer Sally Bridget Lawlor purchased 10,244 ADSs on August 31, 2026 at $4.88 per ADS in a private placement that included 50% warrant coverage. She also acquired 5,122 ordinary warrants exercisable at $6.10 per ADS, which became exercisable immediately subject to a beneficial ownership cap and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following these purchases, she directly owned 10,684 ADSs and 5,122 warrants.
Quoin Pharmaceuticals, Ltd. (QNRX) director Anthony James Culverwell reported buying both ADSs and warrants linked to the company. On 2026-08-31 he purchased 6,146 ADSs at $4.88 per ADS in a private placement that included 50% ordinary warrant coverage, and also acquired 3,073 ordinary warrants with an exercise price of $6.10 per ADS. Each ADS represents 35 ordinary shares. The warrants are exercisable immediately, subject to a beneficial ownership cap, and will expire on the earlier of five years from issuance or 30 days after Quoin publicly announces that the primary endpoint has been met in clinical trial CL-QRX003-004 for Netherton Syndrome. Following the ADS purchase, Culverwell directly held 40,364 ADSs.
Quoin Pharmaceuticals, Ltd. (QNRX) reported that director Dennis Langer acquired 34,534 ADSs on August 27, 2026 in a grant/award-type transaction. The company and Langer entered an exchange agreement under which $177,849 of accrued interest on a previously purchased note was exchanged for these ADSs at $5.15 per ADS. Following this debt-for-equity exchange, Langer directly holds 56,243 ADSs. Each ADS represents 35 ordinary shares of Quoin Pharmaceuticals.
Quoin Pharmaceuticals, Ltd. (QNRX) reported that director Anthony James Culverwell acquired 31,352 ADSs on August 27, 2026 through a grant/award acquisition. The ADSs were issued under an exchange agreement in which $161,461 of accrued interest outstanding on a note he previously purchased was exchanged for these shares, at a reported value of $5.15 per ADS. Following this transaction, he holds 34,218 ADSs directly. Each ADS represents 35 ordinary shares. The exchange agreement and the debt-for-equity exchange were approved in advance by Quoin’s audit committee and board of directors.
Quoin Pharmaceuticals Ltd. (QNRX) entered into a private placement securities purchase agreement with institutional and accredited investors for gross proceeds of up to $50.0 million, including approximately $30.8 million upfront and up to $19.2 million on potential cash exercise of accompanying ordinary warrants. Quoin will issue 6,305,300 ADSs (or pre-funded warrants) and ordinary warrants to purchase up to 3,152,650 ADSs, and expects upfront net proceeds of about $29.0 million, intended for general corporate purposes and completion of QRX003 development, with aggregate net proceeds expected to fund operations into the second half of 2029.
The company also entered exchange agreements issuing 222,574 ADSs to settle approximately $1.146 million of historical note interest. Separately, interim data from the Phase 2/3 CL-QRX003-004 trial in Netherton Syndrome showed 4 of 6 patients (66.67%) achieved the primary IGA endpoint at Week 12 (p=0.0087), significant improvement on a key secondary GIC endpoint (mean change -1.5; p=0.007), and a favorable safety profile with no treatment-related serious adverse events.
Quoin Pharmaceuticals Ltd. (QNRX) reported results of its 2026 Annual General Meeting held on August 20, 2026. Shareholders approved changes to the Company’s 401(k) plan matching contributions, including for U.S.-based executive officers, as described in the Company’s July 16, 2026 proxy statement.
Shareholders also approved amendments to the non-employee directors’ compensation program, increasing the annual base cash retainer to up to $250,000, with the exact amount to be set each year by the Compensation Committee and the Board. The annual option award value range was set between $20,000 and $200,000, also determined annually at their discretion. Other terms of the program remain unchanged. As of the July 15, 2026 record date, there were 70,294,615 ordinary shares outstanding, represented by 2,008,418 ADSs, entitled to vote at the meeting.